Roser Angles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Roser Angles has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
A Salgado
1 shared publicationA. Pardo-Hernández
Departamento de Calidad, Servicio Madrileño de Salud, Madrid, España
1 shared publicationA. Wu
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Estados Unidos
1 shared publication- Alberto Sandiumenge
Donation and Transplantation Program Coordination, Vall d'Hebron Research Institut. Vall d'Hebron University Hospital, Barcelona, Spain
1 shared publication Antonio Roman
Department of Pneumology, Hospital Vail d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
1 shared publicationB. Millan
Hospital General Universitari Vail d’Hebron de Barcelona
1 shared publication
Latest Publications
- 9 October 2013
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 28 (6) , 381-389
Conferencia de consenso sobre información de eventos adversos a pacientes y familiares
- 9 October 2013
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 28 (6) , 381-389
Conferencia de consenso sobre información de eventos adversos a pacientes y familiares
- 1 April 2013
- Published by Elsevier in Medicina Clinica
- Vol. 140 (7) , 320-324
Sistema de notificación genérico y gestión de incidentes: Implantación y acciones de mejora derivadas para la seguridad del paciente
- 1 April 2013
- Published by Elsevier in Medicina Clinica
- Vol. 140 (7) , 320-324
Sistema de notificación genérico y gestión de incidentes: Implantación y acciones de mejora derivadas para la seguridad del paciente
- 1 September 2011
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 32 (3) , 591-599
Prevention of VAP: Is Zero Rate Possible?
- 1 September 2011
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 32 (3) , 591-599
Prevention of VAP: Is Zero Rate Possible?
- 1 July 2008
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 23 (4) , 158-163
Sistemas de identificación de pacientes en hospitales de Cataluña
- 1 July 2008
- Published by Elsevier in Revista de Calidad Asistencial
- Vol. 23 (4) , 158-163
Sistemas de identificación de pacientes en hospitales de Cataluña
- 1 February 2008
- p. 69-76
[Use of neuromuscular blockers in the critical patient].
The use of neuromuscular blockers (NMB) is a frequent practice in Intensive Care Units. However most of the experience with the use of these agents come from the operating room used to deal with patients with different characteristics from those admitted in the ICU. Recent advances on neuromonitoring and the commercialization of newer agents make necessary the update in the management of NMB in the ICU. The NMB agent should be chosen attending to its pharmacokinetics and the physiopathology of the critically ill patient. Those NMB with organ-independent metabolism as well as those with rapid onset of action are the preferred ones for the use in the critically ill patient substituting older depolarizing agents and those whose metabolism is dependent on the liver and/or kidney, organs frequently impaired in the critically ill patients. Neuromuscular blocking in the critically ill patient should be done according to protocols and monitor its effects in order to avoid complications related to its prolonged use.
- 1 February 2008
- p. 69-76
[Use of neuromuscular blockers in the critical patient].
The use of neuromuscular blockers (NMB) is a frequent practice in Intensive Care Units. However most of the experience with the use of these agents come from the operating room used to deal with patients with different characteristics from those admitted in the ICU. Recent advances on neuromonitoring and the commercialization of newer agents make necessary the update in the management of NMB in the ICU. The NMB agent should be chosen attending to its pharmacokinetics and the physiopathology of the critically ill patient. Those NMB with organ-independent metabolism as well as those with rapid onset of action are the preferred ones for the use in the critically ill patient substituting older depolarizing agents and those whose metabolism is dependent on the liver and/or kidney, organs frequently impaired in the critically ill patients. Neuromuscular blocking in the critically ill patient should be done according to protocols and monitor its effects in order to avoid complications related to its prolonged use.
- Open Access
- 1 December 2004
- Published by Frontiers Media SA in Transplant International
- Vol. 17 (12) , 810-814
Lung transplantation for emphysema. Lung hyperinflation: incidence and outcome
Lung transplantation, single or bilateral sequential, is the final option for patients with emphysema. This study analyzed the outcome of lung transplants for emphysema (single or double), and evaluates the incidence, predictive factors and prognosis of lung hyperinflation (LHI) in unilateral transplants. We prospectively studied patients undergoing lung transplantation for emphysema. On admission to the Intensive Care Unit (ICU) and at 12, 24,48 and 72 h we tested the patients’ respiratory function, oxygen arterial pressure (PaO2) and mean pulmonary arterial pressure (MPAP) before transplantation. LHI incidence, duration of mechanical ventilation and hypoxemia, ICU stay and mortality was also analyzed. We studied 34 consecutive patients undergoing lung transplantation for emphysema, 14 single and 20 bilateral. Single-lung transplantation had a higher mortality (50%) than double-lung transplantation (11%), with an odds ratio of 9.0 (1.3–48.7). Of the 14 patients who received a single graft, 9 patients (64%) developed LHI. No predictive factors for LHI could be established. Duration of mechanical ventilation (22 vs 3 days) and ICU stay (36 vs 6 days) was much longer in patients with LHI; however, only ICU stay reached statistical significance (P = 0.011). Mortality in patients with LHI was higher, 67% vs 20% (NS). We conclude that single-lung transplant in emphysema patients has a worse prognosis than bilateral transplant, with a 9-fold higher mortality rate. LHI is a common event in single-lung transplant for emphysema and is associated in our patients with a longer stay at the ICU.
- 1 December 2004
- Published by Frontiers Media SA in Transplant International
- Vol. 17 (12) , 810-814
Open AccessLung transplantation for emphysema. Lung hyperinflation: incidence and outcome
Lung transplantation, single or bilateral sequential, is the final option for patients with emphysema. This study analyzed the outcome of lung transplants for emphysema (single or double), and evaluates the incidence, predictive factors and prognosis of lung hyperinflation (LHI) in unilateral transplants. We prospectively studied patients undergoing lung transplantation for emphysema. On admission to the Intensive Care Unit (ICU) and at 12, 24,48 and 72 h we tested the patients’ respiratory function, oxygen arterial pressure (PaO2) and mean pulmonary arterial pressure (MPAP) before transplantation. LHI incidence, duration of mechanical ventilation and hypoxemia, ICU stay and mortality was also analyzed. We studied 34 consecutive patients undergoing lung transplantation for emphysema, 14 single and 20 bilateral. Single-lung transplantation had a higher mortality (50%) than double-lung transplantation (11%), with an odds ratio of 9.0 (1.3–48.7). Of the 14 patients who received a single graft, 9 patients (64%) developed LHI. No predictive factors for LHI could be established. Duration of mechanical ventilation (22 vs 3 days) and ICU stay (36 vs 6 days) was much longer in patients with LHI; however, only ICU stay reached statistical significance (P = 0.011). Mortality in patients with LHI was higher, 67% vs 20% (NS). We conclude that single-lung transplant in emphysema patients has a worse prognosis than bilateral transplant, with a 9-fold higher mortality rate. LHI is a common event in single-lung transplant for emphysema and is associated in our patients with a longer stay at the ICU.
- 1 March 2001
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 19 (2) , 130-133
Effectiveness and safety of prehospital urapidil for hypertensive emergencies
- 1 March 2001
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 19 (2) , 130-133
Effectiveness and safety of prehospital urapidil for hypertensive emergencies
- 26 June 1999
- Vol. 113 (3) , 81-4
[Reimplantation lesion in the postoperative period of lung transplantation. Incidence, predictive factors, prognosis and outcome. The Lung Transplantation Group of Vall d'Hebron University General Hospital].
Reimplantation disease (RD) is a postoperative complication in lung transplantation. It is defined as hypoxemia (PaO2/FiO2 ratio < 150 mmHg), radiologic infiltrates and decrease of lung compliance. The aim of the study was to analyze the incidence, predictive factors, prognosis and outcome of the patients with RD. 49 patients submitted to lung transplantation (June 1991-December 1996) were admitted in our intensive care unit (ICU). Donor and recipient conditions, surgical parameters and outcome in ICU were analyzed. Mann-Whitney, Kruskall-Wallis, Fisher, Pearson and ANOVA-Friedman tests were used for statistical analysis according to the different variables. 49% of the patients (29/49) developed RD, which was influenced neither by lung disease, nor by the kind of transplantation or by ischemia time. All patients with a long surgical time developed RD, versus only 41% in those where surgery was undertaken in a shorter period of time, OR: 2.8 (1.5-5.7; p = 0.0016). The patients with RD improved showing a PaO2/FiO2 ratio of 176 and 235 mmHg at 24 and 48 h respectively (ANOVA, p < 0.00001). The patients with RD needed 14 days of mechanical ventilation versus 7 days in those without RD (p = 0.013). There were no statistically significant differences in stay and mortality in ICU. RD is a common complication in the postoperative phase of lung transplantation. It is present in almost all the patients with long surgical time. Almost all of them improve, with the same survival but a longer period of mechanical ventilation.
- 26 June 1999
- Vol. 113 (3) , 81-4
[Reimplantation lesion in the postoperative period of lung transplantation. Incidence, predictive factors, prognosis and outcome. The Lung Transplantation Group of Vall d'Hebron University General Hospital].
Reimplantation disease (RD) is a postoperative complication in lung transplantation. It is defined as hypoxemia (PaO2/FiO2 ratio < 150 mmHg), radiologic infiltrates and decrease of lung compliance. The aim of the study was to analyze the incidence, predictive factors, prognosis and outcome of the patients with RD. 49 patients submitted to lung transplantation (June 1991-December 1996) were admitted in our intensive care unit (ICU). Donor and recipient conditions, surgical parameters and outcome in ICU were analyzed. Mann-Whitney, Kruskall-Wallis, Fisher, Pearson and ANOVA-Friedman tests were used for statistical analysis according to the different variables. 49% of the patients (29/49) developed RD, which was influenced neither by lung disease, nor by the kind of transplantation or by ischemia time. All patients with a long surgical time developed RD, versus only 41% in those where surgery was undertaken in a shorter period of time, OR: 2.8 (1.5-5.7; p = 0.0016). The patients with RD improved showing a PaO2/FiO2 ratio of 176 and 235 mmHg at 24 and 48 h respectively (ANOVA, p < 0.00001). The patients with RD needed 14 days of mechanical ventilation versus 7 days in those without RD (p = 0.013). There were no statistically significant differences in stay and mortality in ICU. RD is a common complication in the postoperative phase of lung transplantation. It is present in almost all the patients with long surgical time. Almost all of them improve, with the same survival but a longer period of mechanical ventilation.
- 1 August 1998
- Published by Springer Nature in Intensive Care Medicine
- Vol. 24 (8) , 837-838
Anticoagulative effect of nitric oxide inhalation in ARDS
Some studies have suggested that nitric oxide (NO) may cause platelet dysfunction. We present an ARDS patient who need this treatment, with a transient alteration of platelet function and a significant prolongation of bleeding time.
- 1 August 1998
- Published by Springer Nature in Intensive Care Medicine
- Vol. 24 (8) , 837-838
Anticoagulative effect of nitric oxide inhalation in ARDS
Some studies have suggested that nitric oxide (NO) may cause platelet dysfunction. We present an ARDS patient who need this treatment, with a transient alteration of platelet function and a significant prolongation of bleeding time.
- 1 March 1991
- Vol. 188 (4) , 193-6
[Snake bites in our environment. A biannual review of 7 cases].
The clinical picture, treatment and evolution of seven patients presenting snake bites are analyzed. Local symptoms were constant, with a spontaneous favorable evolution in 7 to 10 days. The most relevant systemic manifestations were coagulation anomalies which appeared in two patients. Treatment always included local wound care, antitetanicum antibiotic and anticoagulant prophylaxis with specific antiophidic serum in five patients.
- 1 March 1991
- Vol. 188 (4) , 193-6
[Snake bites in our environment. A biannual review of 7 cases].
The clinical picture, treatment and evolution of seven patients presenting snake bites are analyzed. Local symptoms were constant, with a spontaneous favorable evolution in 7 to 10 days. The most relevant systemic manifestations were coagulation anomalies which appeared in two patients. Treatment always included local wound care, antitetanicum antibiotic and anticoagulant prophylaxis with specific antiophidic serum in five patients.